Mainz Biomed N.V. (MYNZ)

$0.59 -0.02 (-2.97%)
Market Cap 5.52M
Revenue (ttm) 890,000.00
Net Income (ttm) -21.65M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,432.58%
Debt to Equity Ratio 0.19
Volume 126,100
Avg Vol 540,004
Day's Range N/A - N/A
Shares Out 9.06M
Stochastic %K 11%
Beta 0.26
Analysts Strong Sell
Price Target $14.00

Company Profile

Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fishe...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 49 6131 554 2860
Address:
Robert Koch Strasse 50, Mainz, Germany
Xochi_Resaerch_Group
Xochi_Resaerch_Group Feb. 23 at 9:41 PM
$MYNZ down 95% on this what’s another 5% lol. Goodnight
0 · Reply
ChuckKnuckles50
ChuckKnuckles50 Feb. 23 at 3:58 PM
$MYNZ 5% down every day. Company making your money evaporate and people think I’m the bad guy.
1 · Reply
ChuckKnuckles50
ChuckKnuckles50 Feb. 23 at 1:17 PM
$MYNZ a least everyone will double their share count when they have to r/s to stay compliant.
0 · Reply
tr53
tr53 Feb. 23 at 11:54 AM
$MYNZ Almost nothing
0 · Reply
zerotrust07
zerotrust07 Feb. 20 at 8:45 PM
$MYNZ whats the chances this will be back over a dollar and stay, to meet compliance and before notification from Nasdaq?
0 · Reply
Bigdubs
Bigdubs Feb. 19 at 9:00 PM
$MYNZ Grabbed an entry under .6 with these shell plays a catalyst will hit that I will dump on before heading into the boring phase
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 19 at 7:35 PM
$MYNZ Current Stock Price: $0.57
0 · Reply
ChuckKnuckles50
ChuckKnuckles50 Feb. 19 at 4:34 PM
$MYNZ could we see $.4s here today? Insane selling in this thing
0 · Reply
ChuckKnuckles50
ChuckKnuckles50 Feb. 19 at 2:45 PM
$MYNZ look at that ask. Haha. It’s dead. Suckers
0 · Reply
ChuckKnuckles50
ChuckKnuckles50 Feb. 19 at 2:38 PM
$MYNZ the .5s are here like I said. Haha what trash
0 · Reply
Latest News on MYNZ
Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting

Jan 14, 2026, 9:15 AM EST - 5 weeks ago

Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting

Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America

Nov 18, 2025, 8:01 AM EST - 3 months ago

Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America

Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025

Nov 12, 2025, 8:01 AM EST - 3 months ago

Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025

Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)

Nov 10, 2025, 8:01 AM EST - 3 months ago

Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)

Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

Oct 8, 2025, 9:00 AM EDT - 4 months ago

Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

Mainz Biomed Announces Registration of ColoAlert in the United Kingdom

Sep 2, 2025, 8:01 AM EDT - 6 months ago

Mainz Biomed Announces Registration of ColoAlert in the United Kingdom

Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®

Aug 13, 2025, 8:01 AM EDT - 6 months ago

Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®

Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants

Aug 4, 2025, 10:22 AM EDT - 7 months ago

Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants

Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies

Jul 23, 2025, 8:01 AM EDT - 7 months ago

Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies

Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition

Jul 15, 2025, 8:01 AM EDT - 7 months ago

Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition

Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test

Jun 25, 2025, 8:01 AM EDT - 8 months ago

Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test

Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

Jun 10, 2025, 9:01 AM EDT - 9 months ago

Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants

May 19, 2025, 8:01 PM EDT - 10 months ago

Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants

Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study

May 16, 2025, 8:01 AM EDT - 10 months ago

Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study

Mainz Biomed Enters into Technology Partnership with EDX Medical Group

Apr 29, 2025, 8:01 AM EDT - 10 months ago

Mainz Biomed Enters into Technology Partnership with EDX Medical Group

Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval

Apr 28, 2025, 8:01 AM EDT - 10 months ago

Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval

Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study

Mar 27, 2025, 9:01 AM EDT - 11 months ago

Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study

Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer

Mar 13, 2025, 8:01 AM EDT - 1 year ago

Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer

Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention

Mar 3, 2025, 8:01 AM EST - 1 year ago

Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention

Mainz Biomed Expands into Switzerland with labor team w

Feb 20, 2025, 8:01 AM EST - 1 year ago

Mainz Biomed Expands into Switzerland with labor team w

Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month

Feb 11, 2025, 8:01 AM EST - 1 year ago

Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month

Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements

Jan 27, 2025, 8:01 AM EST - 1 year ago

Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements

Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population

Jan 21, 2025, 8:01 AM EST - 1 year ago

Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test

Dec 19, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test

Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering

Dec 16, 2024, 5:00 PM EST - 1 year ago

Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering

Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules

Dec 12, 2024, 8:00 PM EST - 1 year ago

Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules

Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific

Dec 3, 2024, 2:40 PM EST - 1 year ago

Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific

TMO

Mainz Biomed Announces Stock Split

Nov 29, 2024, 8:45 AM EST - 1 year ago

Mainz Biomed Announces Stock Split

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update

Oct 21, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update

Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version

Oct 8, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025

Oct 1, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025

Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador

Sep 18, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador

Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert

Sep 4, 2024, 4:01 AM EDT - 1 year ago

Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert

Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience

Jul 25, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience

Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test

Jul 9, 2024, 3:01 AM EDT - 1 year ago

Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test

Mainz Biomed Provides Half Year 2024 Corporate Update

Jul 2, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Provides Half Year 2024 Corporate Update

Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024

Jun 3, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024

Mainz Biomed Reports Results of 2024 Annual General Meeting

May 31, 2024, 5:01 PM EDT - 1 year ago

Mainz Biomed Reports Results of 2024 Annual General Meeting

Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting

May 28, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting

Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial

May 20, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial

Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.

May 7, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.

Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic

Apr 25, 2024, 9:29 AM EDT - 1 year ago

Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic

Mainz Biomed Reports Full Year 2023 Financial Results

Apr 9, 2024, 8:01 AM EDT - 2 years ago

Mainz Biomed Reports Full Year 2023 Financial Results

Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment

Mar 19, 2024, 8:01 AM EDT - 2 years ago

Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment

Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options

Mar 18, 2024, 8:01 AM EDT - 2 years ago

Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options

Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations

Mar 12, 2024, 8:01 AM EDT - 2 years ago

Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations

Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Mar 5, 2024, 8:01 AM EST - 2 years ago

Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community

Feb 27, 2024, 8:01 AM EST - 2 years ago

Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community

Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®

Feb 22, 2024, 8:01 AM EST - 2 years ago

Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®

Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy

Feb 21, 2024, 8:01 AM EST - 2 years ago

Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy

Xochi_Resaerch_Group
Xochi_Resaerch_Group Feb. 23 at 9:41 PM
$MYNZ down 95% on this what’s another 5% lol. Goodnight
0 · Reply
ChuckKnuckles50
ChuckKnuckles50 Feb. 23 at 3:58 PM
$MYNZ 5% down every day. Company making your money evaporate and people think I’m the bad guy.
1 · Reply
ChuckKnuckles50
ChuckKnuckles50 Feb. 23 at 1:17 PM
$MYNZ a least everyone will double their share count when they have to r/s to stay compliant.
0 · Reply
tr53
tr53 Feb. 23 at 11:54 AM
$MYNZ Almost nothing
0 · Reply
zerotrust07
zerotrust07 Feb. 20 at 8:45 PM
$MYNZ whats the chances this will be back over a dollar and stay, to meet compliance and before notification from Nasdaq?
0 · Reply
Bigdubs
Bigdubs Feb. 19 at 9:00 PM
$MYNZ Grabbed an entry under .6 with these shell plays a catalyst will hit that I will dump on before heading into the boring phase
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 19 at 7:35 PM
$MYNZ Current Stock Price: $0.57
0 · Reply
ChuckKnuckles50
ChuckKnuckles50 Feb. 19 at 4:34 PM
$MYNZ could we see $.4s here today? Insane selling in this thing
0 · Reply
ChuckKnuckles50
ChuckKnuckles50 Feb. 19 at 2:45 PM
$MYNZ look at that ask. Haha. It’s dead. Suckers
0 · Reply
ChuckKnuckles50
ChuckKnuckles50 Feb. 19 at 2:38 PM
$MYNZ the .5s are here like I said. Haha what trash
0 · Reply
ChuckKnuckles50
ChuckKnuckles50 Feb. 19 at 12:25 PM
$MYNZ none of it matters when they go out of business and have to sell off their tech. Like they are already having to do
0 · Reply
Rawbinhood
Rawbinhood Feb. 18 at 10:51 PM
$MYNZ Okay, going for unaddressed screening market for pancreatic cancer!!!
0 · Reply
Rawbinhood
Rawbinhood Feb. 18 at 10:48 PM
$MYNZ MMMMmmm!!!
1 · Reply
Xochi_Resaerch_Group
Xochi_Resaerch_Group Feb. 18 at 8:22 PM
$MYNZ .60 HAHAHAHAHAA YO WTF
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 18 at 6:21 PM
$MYNZ RSI: 16.30, MACD: -0.1240 Vol: 0.20, MA20: 1.02, MA50: 1.10 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Rawbinhood
Rawbinhood Feb. 18 at 2:41 PM
$MYNZ @ChuckKnuckles50 With all your personal bitterness toward this company with constant ranting about it's a scam, you better be short and a least put money where your mouth, bitter fool!!!
0 · Reply
ChuckKnuckles50
ChuckKnuckles50 Feb. 18 at 2:32 PM
$MYNZ down another 10% at open. There is really no bottom here. Might be to .10s by the weekend.
0 · Reply
Rawbinhood
Rawbinhood Feb. 18 at 1:52 PM
$MYNZ Final 13F filing for last quarter!!!
1 · Reply
feynman52
feynman52 Feb. 18 at 1:31 PM
$MYNZ Armistice quickly reminding everyone they’re still holding. Funny.
1 · Reply
ChuckKnuckles50
ChuckKnuckles50 Feb. 18 at 4:09 AM
$MYNZ the .5s tomorrow are going to hit like crack.
0 · Reply
JDR1983
JDR1983 Feb. 18 at 3:06 AM
$MYNZ In for 10,000
1 · Reply
BreakoutPika
BreakoutPika Feb. 17 at 7:16 PM
$KHC $HD $MYNZ $HYMC ..
0 · Reply